PepGen Inc. (PEPG) Stock

Healthcare · Biotechnology · Member of Other US Stocks

PepGen Inc. (PEPG) closed at USD 2.32 on 2026-10-14, a change of -53.4 % over the past year, with a market capitalization of USD 175.23M.

PepGen Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

PepGen Inc. key figures

Previous close

USD 2.32 (2026-10-14)

1-year change

-53.4 %

Market cap

USD 175.23M

Enterprise value

USD 74.08M

P/E ratio (trailing)

-2.46

P/E ratio (forward)

-2.39

EPS (trailing)

-1.03

EPS (forward)

-1.06

PEG ratio

n/a

Price to book

1.46

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

5.20

Employees

57

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About PepGen Inc.

PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for PepGen Inc. and compare it with other stocks.